SCHEMBL22490765

SCHEMBL22490765

CCc1cncc(-c2ccc(C(=O)OC)c(F)c2)n1

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 11/20 0.44
CYP11B1 P15538 9/20 0.44
MET P08581 6/20 0.43
NPC1 O15118 1/20 0.42
CASP3 P42574 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
S1PR1 P21453 1/20 0.40
PIM1 P11309 1/20 0.39
CSNK2A1 P68400 1/20 0.39
PIM3 Q86V86 1/20 0.39
PIM2 Q9P1W9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24088661 0.86 PIM1 (0.48) CYP11B2CYP11B1RAB9ASMN1; SMN2PIM1
SCHEMBL25607366 0.84 CYP11B2 (0.56) CYP11B2CYP11B1METNPC1CASP3
SCHEMBL21392101 0.83 CTPS1 (0.53) CYP11B2CYP11B1MET
SCHEMBL29489098 0.83 CTPS1 (0.53) CYP11B2CYP11B1MET
SCHEMBL24088755 0.81 CYP11B2 (0.48) CYP11B2CYP11B1METNPC1CASP3
SCHEMBL31676635 0.81 CYP11B2 (0.48) CYP11B2CYP11B1METNPC1CASP3
SCHEMBL22490772 0.80 NPC1 (0.41) CYP11B2CYP11B1METNPC1CASP3
SCHEMBL30415999 0.79 CTPS1 (0.54) CYP11B2CYP11B1METNPC1CASP3
SCHEMBL21392103 0.79 CTPS1 (0.54) CYP11B2CYP11B1METNPC1CASP3
SCHEMBL31676652 0.78 CYP11B2 (0.52) CYP11B2CYP11B1METNPC1CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3717465-B1 COMPOUNDS STEP PHARMA S A S (FR) 2026-01-21 EP disclosed
US-20250263407-A1 Compounds STEP PHARMA S.A.S. (FR) 2025-08-21 US disclosed
US-12319680-B2 Compounds STEP PHARMA S.A.S. (FR) 2025-06-03 US disclosed
US-20230183229-A1 Compounds SYGNATURE DISCOVERY LIMITED (GB) 2023-06-15 US disclosed
US-20230183229-A1 Compounds SYGNATURE DISCOVERY LIMITED (GB) 2023-06-15 US disclosed
US-20230183229-A1 Compounds SYGNATURE DISCOVERY LIMITED (GB) 2023-06-15 US disclosed
US-11505547-B2 Compounds STEP PHARMA S.A.S. (FR) 2022-11-22 US disclosed
US-20210380575-A1 COMPOUNDS SYGNATURE DISCOVERY LIMITED (GB) 2021-12-09 US disclosed
US-20210380575-A1 COMPOUNDS SYGNATURE DISCOVERY LIMITED (GB) 2021-12-09 US disclosed
EP-3717465-A1 COMPOUNDS Step Pharma S.A.S. (FR) 2020-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183229-A1 Compounds UGT1A1, CYP1A1, CYP1B1 CYP11B2 10/4885CYP11B1 9/4885MET 3978/4885
US-12319680-B2 Compounds UGT1A1, CYP1A1, CYP1B1 CYP11B2 10/4885CYP11B1 9/4885MET 3978/4885
US-20250263407-A1 Compounds CYP1A1, UGT1A1, CYP1A2 CYP11B2 9/4885CYP11B1 10/4885MET 3378/4885
US-11505547-B2 Compounds UGT1A1, CYP1A1, CYP1B1 CYP11B2 10/4885CYP11B1 9/4885MET 3978/4885
US-20210380575-A1 COMPOUNDS UGT1A1, CYP1A1, CYP1B1 CYP11B2 10/4885CYP11B1 9/4885MET 3978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.